A61K 47/6853
Carcino-embryonic antigens
Official title: {Carcino-embryonic antigens}
A61K47/6853 (Carcino-embryonic antigens) appears on 144 US grants and 244 published applications in this corpus.
Search patents in A61K- Granted patents
- 144
- Published applications
- 244
- Assignees
- 67
- Inventors
- 365
- Latest grant
- 8 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 2 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 1 | 0 |
| 1999 | 2 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 1 | 3 |
| 2003 | 0 | 2 |
| 2004 | 1 | 1 |
| 2005 | 0 | 3 |
| 2006 | 3 | 2 |
| 2007 | 1 | 2 |
| 2008 | 0 | 2 |
| 2009 | 2 | 3 |
| 2010 | 1 | 5 |
| 2011 | 7 | 9 |
| 2012 | 3 | 4 |
| 2013 | 4 | 9 |
| 2014 | 8 | 16 |
| 2015 | 9 | 23 |
| 2016 | 25 | 20 |
| 2017 | 11 | 16 |
| 2018 | 13 | 11 |
| 2019 | 9 | 13 |
| 2020 | 7 | 8 |
| 2021 | 7 | 9 |
| 2022 | 5 | 14 |
| 2023 | 3 | 13 |
| 2024 | 4 | 18 |
| 2025 | 4 | 23 |
| 2026 | 8 | 15 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Anti-CEA antibody-exatecan analog conjugate and pharmaceutical use thereof8 Sep 2026US 12,728,168 B2Jiangsu Hengrui Medicine Co., Ltd.
- Anti-CEACAM5 antibodies and conjugates and uses thereof8 Sep 2026US 12,729,239 B2Merck Patent GmbH
- Combination therapy for treating cancer25 Aug 2026US 12,714,759 B2City of Hope
- Molecules that bind to CD66e polypeptides11 Aug 2026US 12,703,760 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Anti-CEACAM5 antibodies and uses thereof10 Mar 2026US 12,570,761 B2Sanofi
- Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-vegfr-2 antibodies and anti-pd1/pd-l1 antibodies10 Sep 2026US 2026/0263622 A1
- Crosslinking antibodies10 Sep 2026US 2026/0263646 A1Enlaza Therapeutics, Inc.
- Anti-cea antibodies6 Aug 2026US 2026/0226189 A1Philogen S.P.A.
- Anti-ceacam5 antibody drug conjugates23 Jul 2026US 2026/0207766 A1Bristol-Myers Squibb Company
- Dual payload antibody drug conjugates for the treatment25 Jun 2026US 2026/0174888 A1Araris Biotech AG
Most cited
By later US patents
- Stably tethered structures of defined compositions with multiple functions or binding specificities139US 7,521,056 B2IBC Pharmaceuticals, Inc. · 2009
- Immunoconjugates with an intracellularly-cleavable linkage115US 7,999,083 B2Immunomedics, Inc. · 2011
- PEGylation by the dock and lock (DNL) technique111US 7,666,400 B2IBC Pharmaceuticals, Inc. · 2010
- CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies109US 5,874,540 AImmunomedics, Inc. · 1999
- Immunoconjugates103US 9,447,159 B2Roche Glycart AG · 2016